Track topics on Twitter Track topics that are important to you
The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed
The post Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia appeared first on Pharmaceutical Business review.
Original Article: Silence’s SLN124 gets orphan designation in Europe for β-ThalassemiaNEXT ARTICLE